Skip to content
Austin Top 50
Author:
Leal Therapeutics
Leal Therapeutics Doses First Patient in NeurALS Phase 1/2 Trial of LTX-002 for Amyotrophic Lateral Sclerosis (ALS)
June 23, 2026